Research and Development: Comparing Key Metrics for Viking Therapeutics, Inc. and Protagonist Therapeutics, Inc.

Biotech R&D: Protagonist vs. Viking - A Decade of Innovation

__timestampProtagonist Therapeutics, Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 2014745900022223073
Thursday, January 1, 2015118310006966842
Friday, January 1, 2016257050009000499
Sunday, January 1, 20174618100013741186
Monday, January 1, 20185949700019040000
Tuesday, January 1, 20196500300023559000
Wednesday, January 1, 20207450600031931000
Friday, January 1, 202112600600044981000
Saturday, January 1, 202212621500054234000
Sunday, January 1, 202312016100063806000
Loading chart...

Unveiling the hidden dimensions of data

The Evolution of R&D in Biotech: A Tale of Two Innovators

In the dynamic world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, Protagonist Therapeutics, Inc. and Viking Therapeutics, Inc. have been at the forefront of this evolution. From 2014 to 2023, Protagonist Therapeutics has consistently outpaced Viking Therapeutics in R&D spending, with an average annual increase of approximately 15%. By 2023, Protagonist's R&D expenses surged to nearly double that of Viking's, highlighting their aggressive pursuit of groundbreaking therapies.

Viking Therapeutics, while trailing, has shown a steady growth trajectory, with a notable 187% increase in R&D expenses from 2014 to 2023. This commitment underscores their strategic focus on expanding their therapeutic pipeline. As these companies continue to invest in R&D, they not only drive their own growth but also contribute significantly to the advancement of medical science.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025